Zenshine Pharma Files for Hong Kong IPO with $357M Valuation
Nanjing Zenshine Pharmaceuticals Co., Ltd. submitted its initial public offering (IPO) filing to the Main...
Deals
Moderna Partners with Recordati on mRNA-3927 for Rare Propionic Acidemia
Moderna Inc. (NASDAQ: MRNA) announced a global partnership with Italy‑based Recordati for mRNA-3927, an investigational mRNA...
Illumina Completes $350M SomaLogic Acquisition to Expand Proteomics Portfolio
Illumina (NASDAQ: ILMN) announced the completion of its acquisition of SomaLogic, a leader in data‑driven proteomics...
Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis
Jiangsu Vcare PharmaTech Co., Ltd. announced a partnership with Beijing Sun-Novo Pharmaceutical Research Co., Ltd....
Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift
Kyowa Kirin (TYO: 4151) announced it will cancel its licensing agreement with Amgen (NASDAQ: AMGN) for...
Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611
Tyligand Bioscience Ltd. this week submitted its initial public offering (IPO) filing to the Hong...
Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21
Suzhou Genhouse Bio Co., Ltd. submitted its initial public offering (IPO) filing to the Hong...
Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a licensing agreement with ApolloBio Corp.,...
Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform
Chengdu Kanghua Biological Products Co., Ltd. (SHE: 300841) announced a plan to increase capital investment...
Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered
Lisata Therapeutics announced the termination of its licensing agreement with Qilu Pharmaceutical Co., Ltd. for...
WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases
WuXi Biologics (HKG: 2269) announced a collaboration agreement with Guizhou Sinorda Biomedicineic Co., Ltd. to provide...
NeuShen Therapeutics Raises Series A+ for CNS Drug Development
NeuShen Therapeutics, a Sino‑US biotech focused on central nervous system (CNS) disorders, announced the completion...
Organon Completes $465M JADA System Sale to Laborie Medical
Organon (NYSE: OGN) announced the completed acquisition of its JADA system by Laborie Medical Technologies Corp....
Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing
Distinct Healthcare Holdings Limited, a China‑based private healthcare service provider, released its prospectus this week...
Biogen’s Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus
Biogen Inc. (NASDAQ: BIIB) announced that its investigational litifilimab has received Breakthrough Therapy Designation (BTD) from...
Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal
Seamless Therapeutics, a Germany‑based gene editing company, announced a global strategic research collaboration and license...
Apeloa Partners with MindRank on AI Drug Development Platform
Apeloa Pharmaceutical Co., Ltd. (SHE: 000739), a China‑based contract development and manufacturing organization (CDMO), announced...
IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform
IVD Medical Holding Ltd (HKG: 1931), a China‑based in vitro diagnostic specialist, announced the launch...
Zhaoke Ophthalmology Expands BRIMOCHOL PF Presbyopia Distribution to Singapore and Vietnam
Zhaoke Ophthalmology (HKG: 6622) announced expanded distribution agreements for BRIMOCHOL PF to include Singapore and...